Ideal high sensitivity troponin baseline cutoff for patients with renal dysfunction

Alexander T. Limkakeng; Julian Hertz; Reginald Lerebours; Maragatha Kuchibhatla; James McCord; Adam J. Singer; Fred S. Apple; William F. Peacock; Robert H. Christenson; Richard M. Nowak

doi:10.1016/j.ajem.2021.08.066

Ideal high sensitivity troponin baseline cutoff for patients with renal dysfunction

Alexander T. Limkakeng^*, Julian Hertz, Reginald Lerebours, Maragatha Kuchibhatla, James McCord, Adam J. Singer, Fred S. Apple, William F. Peacock, Robert H. Christenson, Richard M. Nowak

^*Corresponding author for this work

Research output: Contribution to journal › Letter › peer-review

2 Scopus citations

Original language	English
Pages (from-to)	323-324
Number of pages	2
Journal	American Journal of Emergency Medicine
Volume	56
DOIs	https://doi.org/10.1016/j.ajem.2021.08.066
State	Published - Jun 2022
Externally published	Yes

Keywords

Acute coronary syndrome
Acute myocardial infarction
High-sensitivity troponin assays
Renal disease

Access to Document

10.1016/j.ajem.2021.08.066

Cite this

@article{26a7af7c52c94a57b43cadfc2171e59b,

title = "Ideal high sensitivity troponin baseline cutoff for patients with renal dysfunction",

keywords = "Acute coronary syndrome, Acute myocardial infarction, High-sensitivity troponin assays, Renal disease",

author = "Limkakeng, {Alexander T.} and Julian Hertz and Reginald Lerebours and Maragatha Kuchibhatla and James McCord and Singer, {Adam J.} and Apple, {Fred S.} and Peacock, {William F.} and Christenson, {Robert H.} and Nowak, {Richard M.}",

note = "Funding Information: We would like to acknowledge Siemens Healthcare Diagnostics Inc. for their financial support of this project. Financial support was not dependent on the results of the study. Siemens Healthcare Diagnostics Inc. provided salary support for investigators and materials for testing samples. The investigators retained control of the data throughout the entire study and the decision of whether to publish the results. Funding Information: We would like to acknowledge Siemens Healthcare Diagnostics Inc. for their financial support of this project. Financial support was not dependent on the results of the study. Siemens Healthcare Diagnostics Inc. provided salary support for investigators and materials for testing samples. The investigators retained control of the data throughout the entire study and the decision of whether to publish the results.Dr. Limkakeng reports receiving grant funding from Roche Diagnostics, Abbott Laboratories, Siemens Healthineers, Bristol-Myers Squibb, Ischemia Care, LTD, and GE AstraZeneca; and serving as a consultant for BioM{\'e}rieux and ZS Pharma. Dr. Hertz has received research support from Roche Diagnostics and Abbott Laboratories. Dr. McCord has received research support from Roche, Siemens Healthineers, Abbott, and Beckman Coulter and has served as a consultant for Roche and Siemens Healthineers. Dr. Singer reports serving as a consultant for Jansen, Pfizer, BNS, and AstraZeneca. Dr. Apple reports serving on the board of directors for HyTest Ltd. and the advisory board for Siemens Healthcare and Instrumentation Laboratory. He reports serving as a consultant for LumiraDx; he has served as a nonsalaried principle investigator through Hennepin Healthcare Research Institute for Abbott Diagnostics, Abbott Point of Care, Roche Diagnostics, Siemens Healthcare, Quidel/Alere, Ortho Clinical Diagnostics, and Beckman Coulter. He reports serving as an associate editor for Clinical Chemistry. Dr. Peacock reports receiving research grants from Abbott, BrainCheck, ImmunArray, Janssen, Ortho Clinical Diagnostics, Relypsa, and Roche; serving as a consultant for Abbott, AstraZeneca, Bayer, Beckman, Boehringer Ingelheim, Ischemia Care, Dx, ImmunArray, Instrument Labs, Janssen, Nabriva Therapeutics, Ortho Clinical Diagnostics, Relypsa, Roche, Quidel, and Siemens Healthineers; and providing expert testimony for Johnson & Johnson. He also reports stock/ownership interests in AseptiScope Inc., Brainbox Inc., Comprehensive Research Association LLC, Emergencies in Medicine LLC, and Ischemia DC LLC. Dr. Christenson has received fees from Siemens Healthineers for consultancy work on design and conduct of high-sensitivity cardiac troponin I clinical trials and is a consultant for Siemens Healthineers, Roche Diagnostics, Quidel Diagnostics, and Beckman Coulter. Dr. Nowak has received fees from Siemens Healthineers as a consultant for the design and conduct of this trial. He has been or is a consultant for Siemens Healthineers, Roche Diagnostics, Beckman Coulter, Ortho Clinical Diagnostics, and Abbott.",

year = "2022",

month = jun,

doi = "10.1016/j.ajem.2021.08.066",

language = "English",

volume = "56",

pages = "323--324",

journal = "American Journal of Emergency Medicine",

issn = "0735-6757",

}

TY - JOUR

T1 - Ideal high sensitivity troponin baseline cutoff for patients with renal dysfunction

AU - Limkakeng, Alexander T.

AU - Hertz, Julian

AU - Lerebours, Reginald

AU - Kuchibhatla, Maragatha

AU - McCord, James

AU - Singer, Adam J.

AU - Apple, Fred S.

AU - Peacock, William F.

AU - Christenson, Robert H.

AU - Nowak, Richard M.

N1 - Funding Information: We would like to acknowledge Siemens Healthcare Diagnostics Inc. for their financial support of this project. Financial support was not dependent on the results of the study. Siemens Healthcare Diagnostics Inc. provided salary support for investigators and materials for testing samples. The investigators retained control of the data throughout the entire study and the decision of whether to publish the results. Funding Information: We would like to acknowledge Siemens Healthcare Diagnostics Inc. for their financial support of this project. Financial support was not dependent on the results of the study. Siemens Healthcare Diagnostics Inc. provided salary support for investigators and materials for testing samples. The investigators retained control of the data throughout the entire study and the decision of whether to publish the results.Dr. Limkakeng reports receiving grant funding from Roche Diagnostics, Abbott Laboratories, Siemens Healthineers, Bristol-Myers Squibb, Ischemia Care, LTD, and GE AstraZeneca; and serving as a consultant for BioMérieux and ZS Pharma. Dr. Hertz has received research support from Roche Diagnostics and Abbott Laboratories. Dr. McCord has received research support from Roche, Siemens Healthineers, Abbott, and Beckman Coulter and has served as a consultant for Roche and Siemens Healthineers. Dr. Singer reports serving as a consultant for Jansen, Pfizer, BNS, and AstraZeneca. Dr. Apple reports serving on the board of directors for HyTest Ltd. and the advisory board for Siemens Healthcare and Instrumentation Laboratory. He reports serving as a consultant for LumiraDx; he has served as a nonsalaried principle investigator through Hennepin Healthcare Research Institute for Abbott Diagnostics, Abbott Point of Care, Roche Diagnostics, Siemens Healthcare, Quidel/Alere, Ortho Clinical Diagnostics, and Beckman Coulter. He reports serving as an associate editor for Clinical Chemistry. Dr. Peacock reports receiving research grants from Abbott, BrainCheck, ImmunArray, Janssen, Ortho Clinical Diagnostics, Relypsa, and Roche; serving as a consultant for Abbott, AstraZeneca, Bayer, Beckman, Boehringer Ingelheim, Ischemia Care, Dx, ImmunArray, Instrument Labs, Janssen, Nabriva Therapeutics, Ortho Clinical Diagnostics, Relypsa, Roche, Quidel, and Siemens Healthineers; and providing expert testimony for Johnson & Johnson. He also reports stock/ownership interests in AseptiScope Inc., Brainbox Inc., Comprehensive Research Association LLC, Emergencies in Medicine LLC, and Ischemia DC LLC. Dr. Christenson has received fees from Siemens Healthineers for consultancy work on design and conduct of high-sensitivity cardiac troponin I clinical trials and is a consultant for Siemens Healthineers, Roche Diagnostics, Quidel Diagnostics, and Beckman Coulter. Dr. Nowak has received fees from Siemens Healthineers as a consultant for the design and conduct of this trial. He has been or is a consultant for Siemens Healthineers, Roche Diagnostics, Beckman Coulter, Ortho Clinical Diagnostics, and Abbott.

PY - 2022/6

Y1 - 2022/6

KW - Acute coronary syndrome

KW - Acute myocardial infarction

KW - High-sensitivity troponin assays

KW - Renal disease

UR - http://www.scopus.com/inward/record.url?scp=85114731304&partnerID=8YFLogxK

U2 - 10.1016/j.ajem.2021.08.066

DO - 10.1016/j.ajem.2021.08.066

M3 - Letter

C2 - 34482998

AN - SCOPUS:85114731304

SN - 0735-6757

VL - 56

SP - 323

EP - 324

JO - American Journal of Emergency Medicine

JF - American Journal of Emergency Medicine

ER -

Ideal high sensitivity troponin baseline cutoff for patients with renal dysfunction

Keywords

Access to Document

Fingerprint

Cite this